meta
|
evidence
oncology
Living systematic review and meta-analysis
malignant mesothelioma (mMS) - 2nd line (L2)
2
multiple myeloma
bispecific antibody
teclistamab-cqyv
immune chekpoint inhibitors
anti-PD-(L)1
nivolumab based treatment
nivolumab alone
pembrolizumab based treatment
pembrolizumab plus lenalidomide and dexamethasone
pembrolizumab plus pomalidomide and dexamethasone
no study with result for this clinical condition